Showing 3961-3970 of 5957 results for "".
- Oculus Unveils Pentacam Cornea OCThttps://modernod.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/Oculus is introducing the Pentacam Cornea OCT, a tool that combines Scheimpflug technology with the world’s first pericentric OCT scanning system, according to a company news release. The device provides cornea specialists with imaging capabilities, capturing both Scheimpflug
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Haag-Streit Introduces METIS Ophthalmic Microscope Systemhttps://modernod.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/Haag-Streit has introduced the METIS ophthalmic microscope system, which is designed to provide optical performance, ergonomic design, and advanced features tailored for precision and efficiency. Superior Optical Experience The METIS microscope integrates Haag
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Aura Biosciences to Present Phase 2 Data on Belzupacap Sarotalocan for Choroidal Melanoma at Retina Society Annual Meetinghttps://modernod.com/news/aura-biosciences-to-present-phase-2-data-on-belzupacap-sarotalocan-for-choroidal-melanoma-at-retina-society-annual-meeting/2482412/Aura Biosciences announced that final data from its phase 2 study on the suprachoroidal administration of belzupacap sarotalocan (bel-sar) for treating small choroidal melanoma and indeterminate lesions will be presented at the Retina Society Annual Meeting. The event will take place from Septemb
- Yale Study Uncovers How Brain Wiring Begins Before Birthhttps://modernod.com/news/yale-study-uncovers-how-brain-wiring-begins-before-birth/2482409/Researchers at Yale say they have uncovered how the brain begins to wire itself during early development, long before experiences or sensory inputs like sight come into play. The study, published this month in Science, reveals that brain cells start forming networks based on sp
- Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://modernod.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/The University of Houston (UH) College of Optometry is embarking on a study, backed by a $3.3 million grant from the National Eye Institute, to investigate the progression of vision loss in patients with prediabetes and diabetes. The study, led by Associate Professor Wendy Harrison, aims to ident
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- Sandoz Receives FDA Approval for Eylea Biosimilar Enzeevuhttps://modernod.com/news/sandoz-receives-fda-approval-for-eylea-biosimilar-enzeevu/2482396/The FDA has approved Sandoz's Enzeevu (aflibercept-abzv), an Eylea biosimilar, for the treatment of wet age-related macular degeneration (AMD). The approval includes both a 2 mg vial kit and a pre-filled syringe for intravitreal injection. The FDA provisionally